Announced today outcomes from a Phase 1 clinical trial of APD916.

All adverse events in the trial were moderate or moderate in nature. No serious adverse occasions were reported nor were there any significant safety problems with respect to vital signs, ECGs or laboratory tests. APD916 is an extremely potent compound, and we believe that exposures of just one 1 mg or much less could be sufficient for the intended patient population, said William R. Shanahan, M.D., Arena’s Senior Vice President and Chief Medical Officer. We are currently evaluating next steps for this program. .. Arena reports outcomes of APD916 Phase 1 clinical trial for narcolepsy with cataplexy Arena Pharmaceuticals, Inc. announced today outcomes from a Phase 1 clinical trial of APD916, a novel drug applicant uncovered by Arena that targets the histamine H3 receptor for the treating narcolepsy with cataplexy.However, development provides been held back by the side impact profile of ROCK inhibitors, particularly hyperemia. In AMA0076 we believe we have a candidate that can completely harness the potential of the mechanism of actions and thereby give a potential treatment option for this prevalent and significant condition where current remedies usually do not address the requires of many patients. The reduction of amyloid levels is a significant therapeutic objective therefore. Todd Golde and co-workers from the Mayo Clinic Jacksonville survey evidence to claim that prevention of amyloid deposition could be less difficult than curing established Alzheimer’s disease.

Other Posts From Category "men's health":

Related Posts